NDLI: Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Please wait, while we are loading the content...

The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort.

Kinetics of DNA adduct formation in the oral cavity after drinking alcohol

Prevalidation of salivary biomarkers for oral cancer detection.

Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women.

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

Night shift work and hormone levels in women.

Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies.

Aromatic DNA adducts and risk of gastrointestinal cancers: a case-cohort study within the EPIC-Spain.

Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans.

Urinary bladder cancer risk factors in Egypt.

Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure.

Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Bigger, better, sooner--scaling up for success.

Year: 2012 Volume: 21 Issue: 3

Year: 2012 Volume: 21 Issue: 2

Year: 2012 Volume: 21 Issue: 1

Year: 2011 Volume: 20

Year: 2010 Volume: 19

Year: 2009 Volume: 18

Year: 2008 Volume: 17

Year: 2007 Volume: 16

Year: 2006 Volume: 15

Year: 2005 Volume: 14

Year: 2004 Volume: 13

Year: 2003 Volume: 12

Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Limburg, Paul J. Limsui, David Vierkant, Robert A. Tillmans, Lori S. Wang, Alice H. Lynch, Charles F. Anderson, Kristin E. French, Amy J. Haile, Robert W. Harnack, Lisa J. Potter, John D. Slager, Susan L. Smyrk, Thomas C. Thibodeau, Stephen N. Cerhan, James R.
Spatial Coverage	Iowa
Description	Country affiliation: United States Author Affiliation: Limburg PJ ( Division of Gastroenterology & Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. limburg.paul@mayo.edu)
Abstract	BACKGROUND: Postmenopausal hormone (PMH) therapy represents a controversial colorectal cancer (CRC) preventive intervention. Because colorectal carcinogenesis is a heterogeneous process, we evaluated associations between PMH therapy and incident CRC in relation to KRAS mutation status in a population-based cohort of older women [Iowa Women's Health Study (IWHS)]. METHODS: The IWHS enrolled 41,836 randomly selected women, ages 55 to 69 years, in 1986. PMH therapy and other exposure data were recorded at baseline. Tissue samples from prospectively identified CRC cases (n = 507) were analyzed for somatic KRAS mutations (exon 2, codons 12 and 13). Multivariable Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI). RESULTS: PMH therapy (ever vs. never) was inversely associated with KRAS mutation-negative (RR = 0.83; 95% CI, 0.66-1.06; P = 0.14) and KRAS mutation-positive (RR = 0.82; 95% CI, 0.58-1.16; P = 0.27) tumors, although the observed risk estimates were not statistically significant. When anatomic subsite was additionally considered, the strongest association was found for KRAS mutation-negative, distal colorectal tumors (RR = 0.64; 95% CI, 0.43-0.96; P = 0.03). CONCLUSIONS: To our knowledge, we provide the first report of KRAS-defined CRC risks associated with PMH therapy. These data suggest that PMH therapy may reduce CRC risk through mechanisms beyond KRAS mutation status but might provide greater benefits for KRAS mutation-negative than mutation-positive tumors (at least in the distal colorectum). IMPACT: Findings from this prospective cohort study provide novel insights about the molecular biology of PMH therapy-related CRC risk reduction.
File Format	HTM / HTML
ISSN	10559965
e-ISSN	15387755
DOI	10.1158/1055-9965.EPI-11-1168
Journal	Cancer Epidemiology Biomarkers & Prevention
Issue Number	4
Volume Number	21
Language	English
Publisher	American Association for Cancer Research
Publisher Date	2012-04-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Cancer epidemiology Colorectal Neoplasms Etiology Genetics Estrogen Replacement Therapy Adverse Effects Mutation Postmenopause Drug Effects Proto-oncogene Proteins Ras Proteins Epidemiology Iowa Prognosis Prospective Studies Proto-oncogene Proteins P21(ras) Risk Factors Seer Program Randomized Controlled Trial Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Epidemiology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women

Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location

KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Menopausal hormone therapy and risk of colorectal cancer.

Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Similar Documents

Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women

Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location

KRAS Gene Mutation in Colorectal Cancer Is Correlated With Increased Proliferation and Spontaneous Apoptosis

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Menopausal hormone therapy and risk of colorectal cancer.

Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.